Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918380 · ClinicalTrials.gov registry record · NA
Project 3: ACHIEVE- CHD
A NA study of Coronary Heart Disease, sponsored by University Hospitals Cleveland Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05918380: Recruiting NA study of Coronary Heart Disease, sponsored by University Hospitals Cleveland Medical Center.
NCT05918380 is a NA study of Coronary Heart Disease that is actively recruiting participants, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 500 participants, below the 1,462-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918380, a NA study of Coronary Heart Disease, is actively recruiting participants, sponsored by University Hospitals Cleveland Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center will involve three separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Project 2) and coronary heart disease (CHD, Project 3), which drive downstream lifespan inequality. All three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. All three projects will also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 3 of the ACHIEVE GREATER Center.
Primary Outcome
Percent reaching triple goal of BP \<130/80 mm Hg, HbA1c\<5.7% and LDL-C \<130 mg/dl (\<100 if high-risk)
Conditions Studied
Interventions
- BEHAVIORAL PAL2
- OTHER CINEMA
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT05918380 shows while recruiting
NCT05918380 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,462-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Coronary Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which PAL2 is the first listed.
NCT05918380 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05918380 about?
NCT05918380 is a clinical study titled "Project 3: ACHIEVE- CHD". This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities...
What is the current status of trial NCT05918380?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-08-15. Estimated completion is 2027-01-01.
What conditions does trial NCT05918380 study?
This clinical trial studies the following conditions: Coronary Heart Disease.
What interventions are being tested in trial NCT05918380?
The interventions under investigation include: PAL2 (BEHAVIORAL), CINEMA (OTHER).
Who is sponsoring clinical trial NCT05918380?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918380 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05918380's enrollment target sits among peer trials
500 9th of 19 higher than 11 of 19 other Coronary Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
RECRUITING · NA
-
Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids
COMPLETED · NA
-
An IT Approach to Implementing Depression Treatment in Cardiac Patients (iHeart DepCare)
COMPLETED · NA
-
Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease
COMPLETED · NA
-
Walnut Consumption, Endothelial Function, and Biomarkers
COMPLETED · NA
-
Relationship Between the Menstrual Cycle and Heart Disease in Women
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI